

San Francisco

Spring Group Meeting

SPECIALS

Barlogie-Salmon Myeloma Committee

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

Digital Engagement: TBD
 NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pazarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse: Teresa Witcher, BSN, RN
 Patient Advocate: Paul Gater, MPhil
 Pharmaceutical Science: Craig Elg, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Amy Doyle
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Friday, May 2, 2025 4:30 p.m. - 6:30 p.m.
 Room: Pacific HI (Pacific Concourse Level)

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/08/2022; Re-activated: 2/15/2024.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 05/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/01/2023

A062102, "Randomized Phase II Study of Ixerdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 04/04/2024

EEA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. E. Manasanch. Activated: 4/30/19.

EEA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.

Developing Studies

S2508, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe and J.C. Ye.

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchowala. Activated: 3/08/18; Closed: 9/30/19.

Barlogie-Salmon Myeloma Committee

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 03/03/23.

Proposed Studies-Pre-Triage/On Hold

SXXXX, "A Phase III Study for Evaluation of Maintenance Cessation in Patients with Standard Risk Myeloma Achieving Minimal Residual Disease Negativity." Dr. M. Mohyuddin.

SXXXX, "A Phase II Trial of BCMA Bi-Specific T-Cell Engager (BiTE) Teclistamab in Patients with Systemic Light Chain (AL) Amyloidosis." Drs. D. Bhutani and K. Dorritie.

SXXXX, "An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma." Dr. R. Chakraborty.

SXXXX, Developing Smoldering Multiple Myeloma Concept. Drs. P. Hagen and A. Cowan.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S0777/S1211 Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Banerjee R, Sexton R, Cowan A, Rosenberg A, Ailawadhi S, Rajkumar V, Kumar S, Lonial S, Durie B, Richardson P, Usmani S, Hoering A, Orlowski R.. Blood. Jan 2;145(1):75-84, 2025.

<https://pubmed.ncbi.nlm.nih.gov/39321347/>

Submitted Manuscripts

S1702 Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial. Parker T, Rosenthal A, Santhorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. (SWOG S1702). Submitted.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
Banner University Medical Center - Tucson	11	-	-	-	-	5
Boston Medical Center	5	-	-	2	-	-
CWRU Case Comprehensive Cancer Center LAPS	27	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	1	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	-	1	3	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	-	8	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-
Georgia NCI Community Oncology Research Program	19	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-
Heartland Cancer Research NCORP	11	-	3	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	-	1	1
Henry Ford Hospital	-	-	-	-	2	-
Houston Methodist Hospital	10	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	58	-	5	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	2	-	-	-
Lahey Hospital and Medical Center	3	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	3	1
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Cntr	-	-	1	-	-	2
Medical University of South Carolina Minority Underserved NCORP	54	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	9	-	1	-	-	-
Moffitt Cancer Center	45	-	-	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1803	S2005	S2209	S2213	EAA173	EAA181
NCORP of the Carolinas (Prisma Health NCORP)	-	-	2	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	15	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	3	9
Pacific Cancer Research Consortium NCORP	16	-	6	-	-	-
Parker Adventist Hospital	2	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	1	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-
UC Davis Comprehensive Cancer Center LAPS	27	-	5	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	18	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	3	-	-	3
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	1	-	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	16	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	-	-	-	-
University of Rochester LAPS	15	2	2	-	-	3
University of Texas Health Science Center at San Antonio	22	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	27	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	4	2
Upstate Carolina NCORP	4	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	18	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	22	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	-	4	8
ALLIANCE	219	1	5	1	-	-
CCTG	20	-	-	-	-	-
ECOG-ACRIN	184	8	3	-	-	-
NRG	112	1	4	-	-	-
Total	1,293	12	58	7	37	37

